Trial record 1 of 1 for:    ecog and 3311
Previous Study | Return to List | Next Study

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier:
NCT01898494
First received: July 10, 2013
Last updated: NA
Last verified: July 2013
History: No changes posted
  Purpose

This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus positive stage III-IVA oral cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy with chemotherapy may kill any tumor cells that remain after surgery. It is not yet known how much extra treatment needs to be given after surgery.


Condition Intervention Phase
Human Papilloma Virus Infection
Stage III Squamous Cell Carcinoma of the Oropharynx
Stage IVA Squamous Cell Carcinoma of the Oropharynx
Stage IVB Squamous Cell Carcinoma of the Oropharynx
Procedure: therapeutic conventional surgery
Radiation: intensity-modulated radiation therapy
Drug: cisplatin
Drug: carboplatin
Other: laboratory biomarker analysis
Procedure: quality-of-life assessment
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

Resource links provided by NLM:


Further study details as provided by Eastern Cooperative Oncology Group:

Primary Outcome Measures:
  • PFS rate [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
    Defined as the proportion of patients alive and progression-free at 24 months. Kaplan-Meier estimates will be calculated.

  • Accrual rate [ Time Frame: Up to 18 months ] [ Designated as safety issue: No ]
  • Risk distribution [ Time Frame: Up to 18 months ] [ Designated as safety issue: No ]
    A 90% binomial confidence interval will be estimated for the percentage of patients in each risk group.

  • Incidence of Grade 3-4 bleeding events during surgery and positive margins after surgery, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 [ Time Frame: Up to 18 months ] [ Designated as safety issue: No ]
    The percentage will be deemed too high if 13 or more patients reported with grade 3-4 bleeding in the operating room or with positive margins, which corresponds to an empirical rate of 22%. A 90% binomial confidence interval will be estimated for these events.


Secondary Outcome Measures:
  • Toxicity evaluated using the Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 3 years ] [ Designated as safety issue: Yes ]
    The difference between arms will be evaluated using Fisher's exact test.

  • Overall survival [ Time Frame: Time from registration onto the study until death from any cause, assessed up to 3 years ] [ Designated as safety issue: No ]
    Kaplan-Meier estimates will be calculated, along with their corresponding 95% confidence intervals. The median, 1-year, and 2-year survival rates will be estimated.

  • Swallowing function before and after treatment, evaluated using the modified barium swallow (MBS) ratings [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
  • Change in patient reported quality of life (QOL) as measured by Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N) [ Time Frame: Baseline up to 6 months post radiation therapy ] [ Designated as safety issue: No ]
    Patient QOL will be grouped as "improved" (change >= 7 points, 6 mo post-RT vs. baseline), "worsened" (change =< -7 points) and "stable" (-6 =< change =< 6).


Estimated Enrollment: 377
Study Start Date: July 2013
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A (TOS)
Patients undergo transoral surgical resection of the oropharyngeal tumor.
Procedure: therapeutic conventional surgery
Undergo transoral surgical resection
Other: laboratory biomarker analysis
Correlative studies
Procedure: quality-of-life assessment
Ancillary studies
Other Name: quality of life assessment
Experimental: Arm B (TOS, low-dose IMRT)
Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo low-dose IMRT QD five days a week for 5 weeks.
Procedure: therapeutic conventional surgery
Undergo transoral surgical resection
Radiation: intensity-modulated radiation therapy
Undergo low-dose IMRT
Other Name: IMRT
Other: laboratory biomarker analysis
Correlative studies
Procedure: quality-of-life assessment
Ancillary studies
Other Name: quality of life assessment
Experimental: Arm C (TOS, standard-dose IMRT)
Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo standard-dose IMRT QD five days a week for 6 weeks.
Procedure: therapeutic conventional surgery
Undergo transoral surgical resection
Radiation: intensity-modulated radiation therapy
Undergo standard-dose IMRT
Other Name: IMRT
Other: laboratory biomarker analysis
Correlative studies
Procedure: quality-of-life assessment
Ancillary studies
Other Name: quality of life assessment
Experimental: Arm D (TOS, standard-dose IMRT, chemotherapy)
Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo standard-dose IMRT QD five days a week for 6-7 weeks. Patients also receive cisplatin IV over 30 minutes or carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiation therapy.
Procedure: therapeutic conventional surgery
Undergo transoral surgical resection
Drug: cisplatin
Given IV
Other Names:
  • CACP
  • CDDP
  • CPDD
  • DDP
Drug: carboplatin
Given IV
Other Names:
  • Carboplat
  • CBDCA
  • JM-8
  • Paraplat
  • Paraplatin
Radiation: intensity-modulated radiation therapy
Undergo standard-dose IMRT
Other Name: IMRT
Other: laboratory biomarker analysis
Correlative studies
Procedure: quality-of-life assessment
Ancillary studies
Other Name: quality of life assessment

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • REGISTRATION TO SURGERY (ARM S)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Patients must have newly diagnosed, histologically or cytologically confirmed squamous cell carcinoma or undifferentiated carcinoma of the oropharynx; patients must have been determined to have resectable oropharyngeal disease; patients with primary tumor or nodal metastasis fixed to the carotid artery, skull base or cervical spine are not eligible
  • Patients must have American Joint Committee on Cancer (AJCC) TNM tumor stage III, IV a, or IV b (with no evidence of distant metastases) as determined by imaging studies (performed < 4 weeks prior to pre-registration) and complete head and neck exam; the following imaging is required: computed tomography (CT) scan with IV contrast or magnetic resonance imaging (MRI)
  • Primary: patients must have measurable disease of the primary by both clinical and radiographic methods; to meet this criteria, a lesion must be > 2 cm in at least one dimension by clinical exam AND by radiographic exam with CT or MRI; if radiographic exam utilizes spiral CT, lesion must be > 1cm in at least one dimension; Nodes: although it is required that patients must have nodal stage beyond N0 confirmed by clinical or radiographic methods, measurable nodal disease is not required
  • Carcinoma of the oropharynx associated with HPV as determined by p16 protein expression using immunohistochemistry (IHC) performed by a Clinical Laboratory Improvement Amendments (CLIA) approved laboratory; using p16 antibody obtained from Roche mtm laboratories AG (CINtec, clone E6H4) is recommended
  • No prior radiation above the clavicles
  • Patients with a history of a curatively treated malignancy must be disease-free for at least two years except for carcinoma in situ of cervix and/or non-melanomatous skin cancer
  • Patients with the following within the last 6 months prior to pre-registration must be evaluated by a cardiologist and/or neurologist prior to entry into the study
  • Patients must not have evidence of extensive or "matted/fixed" pathologic adenopathy on preoperative imaging
  • Absolute neutrophil count >= 1,500/mm^3
  • Platelets >= 100,000/mm^3
  • Total bilirubin =< the upper limit of normal (ULN)
  • Calculated creatinine clearance must be > 60 ml/min using the Cockcroft-Gault formula
  • Women must not be pregnant or breast-feeding due to the teratogenicity of chemotherapy; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • Patient must not have an intercurrent illness likely to interfere with protocol therapy or prevent surgical resection
  • Patients must not have uncontrolled diabetes, uncontrolled infection despite antibiotics or uncontrolled hypertension within 30 days prior to pre-registration
  • REGISTRATION/RANDOMIZATION TO STEP 2 - ARMS A, B, C AND D AND REGISTRATION TO STEP 3
  • Histopathologic assessment of surgical pathology must include examination for perineural invasion (PNI) and lymphovascular invasion (LVI) and reported as absent or present; the absence or presence of extracapsular spread (ECS) requires gross and microscopic assessment and is defined to be:

    • Absent (negative or nodal metastasis with smooth/rounded leading edge confined to thickened capsule/pseudocapsule),
    • Present - minimal (tumor extends < 1 mm beyond the lymph node capsule), or
    • Present - extensive (gross, tumor extends > 1 mm beyond the lymph node capsule (includes soft tissue metastasis)
  • Patients must have ECOG performance status 0 or 1
  • Patient must be registered/randomized within 5-7 weeks following surgery
  • Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraception
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01898494

Locations
United States, Massachusetts
Eastern Cooperative Oncology Group
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Eastern Cooperative Oncology Group
Investigators
Principal Investigator: Robert Ferris Eastern Cooperative Oncology Group
  More Information

No publications provided

Responsible Party: Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier: NCT01898494     History of Changes
Other Study ID Numbers: E3311, NCI-2013-00814, U10CA021115
Study First Received: July 10, 2013
Last Updated: July 10, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Squamous Cell
Papilloma
Virus Diseases
Oropharyngeal Neoplasms
Warts
Papillomavirus Infections
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
DNA Virus Infections
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases
Cisplatin
Carboplatin
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 20, 2014